Genetic Counselling and Genetic Screening for Alzheimer's Disease and Other Dementias

Canadian Journal of Neurological Sciences

Volumn 28, Issue S1, 2001, Pages S52-S55

  Sadovnick, A Dessa ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CONFERENCE PAPER; DEMENTIA; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SCREENING; HEREDITY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ALZHEIMER DISEASE; DEMENTIA; GENETIC COUNSELING; GENETIC SCREENING; HUMANS; MIDDLE AGED;

EID: 0035099556     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100001207     Document Type: Article

References (31)

1. Canadian Study of Health and Aging (CSHA) Working Group. CSHA: The incidence of dementia in Canada. Neurology. 2000; 55: 66–73.
2. Rosenberg, RN. The molecular and genetic basis of AD: The end of the beginning. The 2000 Wartenberg lecture. Neurology. 2000; 54: 2045–2054.
3. Froelich, S, Basun, H, Forsell, C, et al. Mapping of a disease locus for familial rapidly progressive frontotemporal dementia to chromosome 17q12–21. Am J Med Genet (Neuropsychiatric Gen). 1997; 74: 380–385.
4. Arima, K, Kowalska, A, Hasegawa, M, et al. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology. 2000; 54: 1787–1795.
5. Corder, EH, Saunders, AM, Strittmatter, WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science. 1993; 261: 921–923.
6. Saunders, AM, Strittmatter, WJ, Schmechel, D, et al. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993; 43: 1467–1472.
7. Poirier, J, Davignon, J, Bouthillier, D, et al. Apolipoprotein E poly-morphism and Alzheimer's disease. Lancet. 1993; 342: 697–699.
8. Grimaldi, LM, Casadei, VM, Ferri, C, et al. Association of early-onset Alzheimer's disease with an interleukin-1 α gene polymorphism. Neurology. 2000; 47: 361–365.
9. Nicoll, JA, Mrak, RE, Graham, DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann Neurol. 2000; 47: 365–368.
10. Ghanbari, H, Ghanbari, K, Beheshti, I, et al. Biochemical assay for AD7C-NTPin urine as an Alzheimer's disease marker. J Clin Lab Anal. 1998, 12: 285–288.
11. Jeffries, W, Feldman, H, Nurminen, J, et al. Serum p97 as a screening test for Alzheimer's disease. Neurobiol Aging. 1998; 19(4s):S82.
12. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the working group on: “Molecular and biochemical markers of Alzheimer's disease”. Neurobiol Aging. 1998; 19: 109–116.
13. Fraser, FC. Genetic counselling. Am J Hum Genet. 1974; 26: 636–659.
14. Claus, EB, Schildkraut, JM, Thompson, WD, Risch, NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996; 77: 2318–2324.
15. Wiggins, S, Whyte, P, Huggins, M, et al. The psychological consequences of predictive testing for Huntington's disease. N Engl J Med. 1992; 327: 1401–1405.
16. ASHG Statement. Professional disclosure of familial genetic information. Am J Hum Genet. 1998; 62: 474–483.
17. Schellenberg, GD, Payami, H, Wijsman, E, et al. Chromosome 14 and late-onset familial Alzheimer's disease (FAD). Am J Hum Genet. 1994; 53: 619–628.
18. Pericak-Vance, MA, Grubber, J, Bailey, LR, et al. Genomic screen of 739 sibpairs with late-onset Alzheimer's disease. Am J Hum Genet. 2000; 67(4):48.
19. Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental-state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–198.
20. Clark, CM, Sheppard, L, Fillenbaum, GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer's disease. Arch Neurol. 1999; 56: 857–862.
21. Hirst, C, Sadovnick, AD, Yee, IML. Familial risks for Alzheimer's disease: data from an Alzheimer's clinic population. Genetic Epidemiol. 1994; 11: 365–374.
22. Bird, TD. Apolipoprotein genotyping in the diagnosis of Alzheimer's disease: a cautionary view. Ann Neurol. 1995; 38: 2–4.
23. Roses, AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol. 1995; 38: 6–14.
24. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer's Disease. Statement on use of Apolipoprotein E testing for Alzheimer's disease. J Am Med Assoc. 1995; 274: 1627–1629.
25. Blacker, D, Haines, JL, Rodes, L, et al. ApoE-4 and age at onset of Alzheimer's disease: The NIMH Genetics Initiative. Neurology. 1997; 48: 139–147.
26. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet. 1996; 347: 1091–1095.
27. Post, SG, Whitehouse, PJ, Binstock, RH, et al. Consensus statement: the clinical introduction of genetic testing for Alzheimer's disease. JAMA. 1997; 277: 832–840.
28. Kalaria, RN, Giacobini, E. Meeting Report: The Fifth International Conference on Alzheimer's Disease and related Disorders. Alzheimer Dis Assoc Disord. 1997; 11: 113–119.
29. Blacker, N. New insights into genetic aspects of Alzheimer's disease. Does genetic information make a difference in clinical practice? Postgrad Med. 2000; 108: 119–122.
30. Patterson, CJS, Gauthier, S, Bergman, H, et al. The recognition and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J. 1999; 160 (supplement 12).
31. Sadovnick, AD. Genetic counselling in dementia. In: Qizilbash, N, Schneider, L, Chui, H, Tariot, P, Brodaty, H, Kaye, J, Erkinjuntti, T eds. Evidence-Based Dementia: A Practical Guide to Diagnosis and Management (with internet updates). Oxford: Blackwells. In press, 2001.